<DOC>
	<DOCNO>NCT01085097</DOCNO>
	<brief_summary>The study aim evaluate safety clinical effect daily oral treatment laquinimod capsule active lupus nephritis patient . This study ass Laquinimod dose 0.5mg /day 1 mg/day combination standard care treatment ( mycophenolate mofetil corticosteroid ) . Laquinimod novel immunomodulating drug currently advance stage development Teva Pharmaceuticals Ltd. Multiple Sclerosis .</brief_summary>
	<brief_title>Laquinimod Study Systemic Lupus Erythematosus ( SLE ) Patients With Active Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>1 . Subjects diagnose SLE 2 . Kidney biopsy within 12 month prior baseline histological diagnosis proliferative membranous Lupus Nephritis 3 . Clinically active Lupus Nephritis evident urine protein creatinine ratio 1 . Subjects severe renal impairment dialysis 2 . Subjects clinically significant unstable medical surgical condition 3 . Women pregnant nursing intend study period . 4 . Women childbearing potential practice acceptable method birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Systemic Lupus Erythematosus ( SLE )</keyword>
	<keyword>Lupus Nephritis</keyword>
	<keyword>Laquinimod</keyword>
</DOC>